Drug Trial Radar · NCT07522099
Chinese Adults With Kidney Disease
Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
May 21, 2026
Primary completion
Jul 10, 2028
Study completion Jan 21, 2029
Sponsor
- Lead sponsor
- ADARx Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).
Conditions
- Immunoglobulin A Nephropathy (IgAN)
- Complement 3 Glomerulopathy (C3G)
- IC-MPGN
Interventions
ADX-038Drug
siRNA duplex oligonucleotide
TelitaciceptDrug
fusion protein
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety and tolerability of ADX-038 as a monotherapy and in combination with telitaciceptTime frame: Part A - 24 Months and Part B - 15 months
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
ADARx Clinical Site
Beijing, China · Recruiting
ADARx Clinical Site
Shandong, China · Recruiting
ADARx Clinical Site
Shanghai, China · Recruiting
ADARx Clinical Site
Shenzhen, Guangdong, China · Recruiting
ADARx Clinical Site
Guiyang, Guizhou, China · Recruiting
ADARx Clinical Site
Zhengzhou, Henan, China · Recruiting
ADARx Clinical Site
Baotou, Inner Mongolia, China · Recruiting
ADARx Clinical Site
Wuxi, Jiangsu, China · Recruiting
ADARx Clinical Site
Yantai, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.